Co-diagnostics(us:CODX)

    0.7154

    -2.00%

    Updated on 2024-12-23

    Open:0.7280
    Close:0.7154
    High:0.7500
    Low:0.7020
    Pre Close:0.7300
    Volume:168219.00
    Amount:121552.69
    Turnover:0.53%
    Shares:31.93M
    MarketCap:22.84M
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-3047464302014.55%81311
    2024-03-3148436068413.94%2623
    2023-12-3149468679414.99%41214
    2023-09-3052448812614.64%6717
    2023-06-3059442648214.38%5830
    2023-03-3167538319717.57%81428
    2022-12-3174587891619.04%81235
    2022-09-3085628307320.32%131436
    dateorgNametotalratiochangeShareschangeRatio
    2024-03-31Vanguard Group Inc17812835.69%0
    2024-03-31Renaissance Technologies Llc6004001.92%-16600-2.69%
    2024-03-31Blackrock Inc.5000501.60%-1780-0.35%
    2024-03-31Geode Capital Management, Llc2944220.94%0
    2024-03-31Bridgeway Capital Management, Llc2729000.87%0
    2024-03-31Kestra Advisory Services, Llc1489410.48%103347.46%
    2024-03-31Bank Of New York Mellon Corp1370670.44%-8554-5.87%
    2024-03-31State Street Corp1006470.32%0
    2024-03-31Susquehanna International Group, Llp946630.30%-13036-12.10%
    2024-03-31Citadel Advisors Llc729310.23%-23716-24.54%

    About

    Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
    Address:2401 South Foothill Drive,Suite D

    Market Movers